These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 20698227)

  • 1. Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?
    Yonem O; Arslan S; Sokmensuer C; Salmanzade S
    Hepatogastroenterology; 2010; 57(99-100):562-6. PubMed ID: 20698227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation does not prevent ribavirin-induced anemia.
    González H; Ríos ME; Torres EA; Muñoz H; Arroyo J; Castro FJ
    P R Health Sci J; 2003 Dec; 22(4):359-62. PubMed ID: 14768501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Sho Y; Fujisaki K; Sakashita H; Yamaguchi K; Tahara K; Kubozono O; Ido A; Tsubouchi H
    J Gastroenterol; 2004 Dec; 39(12):1202-4. PubMed ID: 15622486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
    Ancel D; Amiot X; Chaslin-Ferbus D; Hagege I; Garioud A; Girot R; Pol S; Grange JD
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):726-9. PubMed ID: 19404206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
    Orāşan O; Cozma A; Rednic N; Sâmpelean D; Pârvu A; Petrov L
    Rom J Intern Med; 2009; 47(3):217-25. PubMed ID: 20446436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
    De Franceschi L; Fattovich G; Turrini F; Ayi K; Brugnara C; Manzato F; Noventa F; Stanzial AM; Solero P; Corrocher R
    Hepatology; 2000 Apr; 31(4):997-1004. PubMed ID: 10733558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of angiogenesis soluble markers in chronic hepatitis C.
    Salcedo X; Medina J; Sanz-Cameno P; García-Buey L; Martín-Vilchez S; Borque MJ; López-Cabrera M; Moreno-Otero R
    Hepatology; 2005 Sep; 42(3):696-701. PubMed ID: 16104024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability.
    Seki R; Okamura T; Ide T; Kage M; Sata M; Uyesaka N; Maruyama T
    J Physiol Sci; 2007 Feb; 57(1):43-9. PubMed ID: 17204208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.
    Kamar N; Boulestin A; Selves J; Esposito L; Sandres-Saune K; Stébenet M; Chatelut E; Durand D; Rostaing L; Izopet J
    J Med Virol; 2005 May; 76(1):61-8. PubMed ID: 15778976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing ribavirin-induced hemolysis.
    Van Vlierbergh H; Delanghe JR; De Vos M; Leroux-Roel G;
    J Hepatol; 2001 Jun; 34(6):911-6. PubMed ID: 11451176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin].
    Janczewska-Kazek E; Marek B; Pisula A; Kajdaniuk D; Witor A; Magiera M; Witor A
    Wiad Lek; 2007; 60(3-4):120-3. PubMed ID: 17726862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
    J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin.
    Lin CC; Yin MC
    Clin Nutr; 2009 Feb; 28(1):34-8. PubMed ID: 19042060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between response to pegylated interferon/ribavirin therapy and ribavirin levels.
    Dai CY; Yu ML; Chuang WL
    Hepatology; 2015 Jan; 61(1):408-9. PubMed ID: 24752986
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemolytic anemia and the treatment of chronic hepatitis C.
    Saab S; Martin P
    J Clin Gastroenterol; 1999 Jun; 28(4):289-90. PubMed ID: 10372922
    [No Abstract]   [Full Text] [Related]  

  • 18. The next step for taribavirin.
    Kwo PY; Vinayek R
    Hepatology; 2010 Oct; 52(4):1185-8. PubMed ID: 20879028
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid CO breath test screening of drugs for protective effects on ribavirin-induced hemolysis in a rabbit model: a pilot study.
    Ma YJ; Zhang HD; Wu CH; Zhu GL; Ji YQ; Huang JL; Du LT; Cao P; Zang DY; Ji KM
    J Breath Res; 2016 Aug; 10(3):036010. PubMed ID: 27506143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply: To PMID 24449403.
    Holmes JA; Matthews GV; Thompson AJ;
    Hepatology; 2015 Jan; 61(1):409. PubMed ID: 24915780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.